WideTrial Partners With Oncotelic to Bring Expanded Access Platform to Cancer
WideTrial , one of TrialStat’s strategic partners has partnered with Oncotelic to bring the Expanded Access Platform to Cancer.
June 03, 2019 (ACCESSWIRE via COMTEX) — SAN FRANCISCO, CA / ACCESSWIRE / June 3, 2019 / WideTrial Inc., a third-party sponsor of Expanded Access programs, has begun a partnership with Oncotelic Inc., a wholly owned subsidiary of Mateon Therapeutics Inc., to provide OT-101 to patients who cannot take part in research trials of the investigational product. Under the partnership, WideTrial will sponsor and manage programs for treatment use of OT-101 in pancreatic cancer, advanced melanoma, colorectal cancer, and glioblastoma.
Discover What Sets TrialStat Apart From Ordinary EDC Platforms
Click the image or button below to explore our eClinical Suite Platform and discover what sets TrialStat apart from competing EDC platforms.
Request Your Demo Today!
From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?